{"id":"W4378530156","doi":"10.1016/j.ctrv.2023.102584","title":"The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review","year":2023,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; University of British Columbia; BC Cancer Agency; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Dalhousie University; University of Toronto; McMaster University","funders":"","keywords":"Sorafenib; Medicine; Bevacizumab; Oncology; Durvalumab; Atezolizumab; Internal medicine; Hepatocellular carcinoma; Clinical trial; Regimen; Immunotherapy; Cancer; Nivolumab; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002785317,0.000929223,0.00679854,0.004119999,0.0002848284,0.001861027,0.001159751,0.001325428,0.004046897],"category_scores_gemma":[0.009113568,0.0006490815,0.006756955,0.005934014,0.0004267693,0.001400856,0.0009276762,0.001326366,0.0003236786],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001435961,"about_ca_system_score_gemma":0.003186042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00509461,"about_ca_topic_score_gemma":0.01857065,"domain_scores_codex":[0.9983189,0.0004645569,0.0006521951,0.0002019486,0.0002921266,0.00007027982],"domain_scores_gemma":[0.9946259,0.00349378,0.001363631,0.00007061027,0.0003591012,0.00008692438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0006560252,0.00003159055,0.0009032427,0.8706831,0.027058,0.00009471665,0.00008986906,0.0002571998,0.0003172682,0.0002526127,0.003252882,0.09640356],"study_design_scores_gemma":[0.001134489,0.0005810282,0.00871425,0.6098797,0.3257197,0.0005816352,0.0002353633,0.0002370742,0.0002753767,0.0006391029,0.05191716,0.00008501397],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002811334,0.9993863,0.00003502987,0.00006284982,0.00004888698,0.00002239992,0.00007760509,0.000002286461,0.00008350773],"genre_scores_gemma":[0.004132489,0.9952716,0.0001471589,0.0002598145,0.00004458704,0.00003155164,0.00005839321,0.000001869108,0.00005241457],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00679854,"threshold_uncertainty_score":0.01473027,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1175993671776607,"score_gpt":0.3477802134063483,"score_spread":0.2301808462286876,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}